Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Aumolertinib；midazolam

Phase 1Small molecule

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Aumolertinib；midazolam is one of 2 small molecule programs targeting Midazolam. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

MidazolamRecruiting

MidazolamPhase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Midazolam

#DrugCompanyPhaseTrials

Aumolertinib；midazolam

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Midazolam With Fentanyl

YYonsei University

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Midazolam1 trial

A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC

Recruiting· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT06926413·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Aumolertinib；midazolam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aumolertinib；midazolam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aumolertinib；midazolam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Hansoh Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Related News